NASDAQ:JNCE - Jounce Therapeutics Stock Price, Forecast & News

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

Jounce Therapeutics Inc (NASDAQ:JNCE) posted its quarterly earnings results on Thursday, November, 7th. The company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.24 by $0.66. The company had revenue of $119.45 million for the quarter, compared to the consensus estimate of $99.97 million. Jounce Therapeutics had a return on equity of 64.54% and a net margin of 46.11%. View Jounce Therapeutics' Earnings History.

Jounce Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Jounce Therapeutics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Jounce Therapeutics.

Media coverage about JNCE stock has been trending very negative on Friday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Jounce Therapeutics earned a media sentiment score of -3.6 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Jounce Therapeutics.

Jounce Therapeutics saw a increase in short interest in December. As of December 31st, there was short interest totalling 1,760,000 shares, an increase of 15.0% from the December 15th total of 1,530,000 shares. Based on an average daily volume of 667,400 shares, the short-interest ratio is presently 2.6 days. Approximately 11.2% of the company's stock are short sold. View Jounce Therapeutics' Current Options Chain.

Some companies that are related to Jounce Therapeutics include Krystal Biotech (KRYS), BAVARIAN NORDIC/S (BVNRY), Atara Biotherapeutics (ATRA), AVITA MED LTD/S (RCEL), Mesoblast (MESO), Cellectis (CLLS), Vericel (VCEL), GENFIT S A/ADR (GNFT), Adverum Biotechnologies (ADVM), Twist Bioscience (TWST), MeiraGTx (MGTX), Avrobio (AVRO), Rubius Therapeutics (RUBY), Osiris Therapeutics (OSIR) and AVITA MED LTD/S (AVMXY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Jounce Therapeutics investors own include Exelixis (EXEL), Neurocrine Biosciences (NBIX), Teva Pharmaceutical Industries (TEVA), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), Amarin (AMRN), EXACT Sciences (EXAS) and Netflix (NFLX).

(JNCE) raised $76 million in an initial public offering on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of JNCE stock can currently be purchased for approximately $7.24.

Jounce Therapeutics has a market capitalization of $240.58 million and generates $65.20 million in revenue each year. The company earns $-27,380,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Jounce Therapeutics employs 115 workers across the globe.View Additional Information About Jounce Therapeutics.

The official website for Jounce Therapeutics is http://www.jouncetx.com/.

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.